BioAtla, Inc. is set to present updated results from its Phase 1 study of evalstotug (BA3071), a conditionally active anti-CTLA-4 biologic, in patients with advanced solid tumors at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, TX. The data highlight the potential of evalstotug, designed to improve safety and efficacy over traditional CTLA-4 inhibitors. Additionally, BioAtla will present data at the Society for Melanoma Research (SMR) 21st International Congress.
Evalstotug (BA3071) in Advanced Solid Tumors
The poster presentation at SITC, scheduled for November 8, 2024, will feature updated findings from the Phase 1 trial evaluating evalstotug, both as a monotherapy and in combination with nivolumab, in patients with advanced solid tumors. Evalstotug, a novel CTLA-4 inhibitor, leverages BioAtla's Conditionally Active Biologics (CAB) technology to selectively target the tumor microenvironment, reducing systemic toxicity typically associated with CTLA-4 inhibition. This approach potentially enables safer and more effective combination therapies with checkpoint inhibitors like anti-PD-1 antibodies.
Oral Presentation at Society for Melanoma Research
BioAtla will also present an oral presentation at the Society for Melanoma Research (SMR) 21st International Congress on October 11, 2024. The presentation will focus on the design and potential benefits of evalstotug, emphasizing its ability to enable high exposures, extended dosing, and reduced immune-mediated toxicity. The presentation abstract title is "Evalstotug (BA3071): a potent conditionally active biologic (CAB) anti-CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity".
CAB Technology and its Clinical Implications
BioAtla's CAB technology is designed to develop novel, reversibly active monoclonal and bispecific antibodies. These CAB product candidates aim for more selective targeting, greater efficacy with lower toxicity, and more cost-efficient manufacturing compared to traditional antibodies. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC). The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development, targeting EpCAM while engaging human CD3 expressing T cells.
